Shire Sues Impax Again Over New Adderall ANDAs

Law360, New York (January 16, 2005, 12:00 AM EST) -- U.K. drug maker Shire Pharmaceuticals has filed a second lawsuit against U.S. generics maker Impax Labs based on an abbreviated new drug application for another dosage of best-selling attention-deficit drug Adderall XL.

Shire, which has already sued Impax over its Paragraph IV notice letter for a 30 mg generic version of Adderall XR, has filed a second complaint based on an additional Paragraph IV notice letter for a generic version of the 5 mg, 10 mg, 15 mg, 20 mg and 25 mg strengths of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.